Joseph Meserve

Statistics

Publications

Citations

840

H-Index

Active since

2015

Affiliations

University of California San Diego(Current)

New York University

Icahn School of Medicine at Mount Sinai

Dartmouth–Hitchcock Medical Center

Indiana University – Purdue University Indianapolis

Joseph Meserve is an author at University of California San Diego specializing in pharmacotherapy, inflammatory bowel disease, and vedolizumab therapy.

ORCID

Publications per year

2015–2025

Publications

Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Neeraj Narula, Farhad Peerani, Joseph Meserve et al. · The American Journal of Gastroenterology · 2018 · 175 citations

Medicine, Internal Medicine, Pharmacotherapy +15

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn’s Disease

Parambir S. Dulai, Brigid S. Boland, Siddharth Singh et al. · Gastroenterology · 2018 · 149 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases

Joseph Meserve, Satimai Aniwan, Jenna L. Koliani‐Pace et al. · Clinical Gastroenterology and Hepatology · 2018 · 83 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

Parambir S. Dulai, Siddharth Singh, Niels Vande Casteele et al. · Clinical Gastroenterology and Hepatology · 2020 · 79 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17

Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease

Eugenia Shmidt, Gursimran Kochhar, Justin Hartke et al. · Inflammatory Bowel Diseases · 2018 · 76 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

1–5 of 16